Evidence map›Paper›PMID 38548918›Full record

ArticleClinical & experimental metastasis2024

Transcriptomic characterization of the histopathological growth patterns in breast cancer liver metastases.

Sophia Leduc, Ha-Linh Nguyen, François Richard, Gitte Zels, Amena Mahdami, Maxim De Schepper, Marion Maetens, Anirudh Pabba, Joris Jaekers, Emily Latacz and 16 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical & experimental metastasis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 5 institutions in 1 country.

Sophia Leduc *Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Herestraat 49, box 810, Leuven, 3000, Belgium.
Ha-Linh Nguyen *Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Herestraat 49, box 810, Leuven, 3000, Belgium.
François RichardLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Herestraat 49, box 810, Leuven, 3000, Belgium.
Gitte ZelsLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Herestraat 49, box 810, Leuven, 3000, Belgium.
Amena MahdamiLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Herestraat 49, box 810, Leuven, 3000, Belgium.
Maxim De SchepperLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Herestraat 49, box 810, Leuven, 3000, Belgium.
Marion MaetensLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Herestraat 49, box 810, Leuven, 3000, Belgium.
Anirudh PabbaLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Herestraat 49, box 810, Leuven, 3000, Belgium.
Joris JaekersDepartment of Visceral Surgery, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Emily LataczTranslational Cancer Research Unit, GZA Hospitals Antwerp, Antwerp, Belgium.
Ali BohlokDepartment of Surgical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Evy VanderheydenLaboratory of Translational Genetics, VIB-KU Leuven, Leuven, Belgium.
Thomas Van BrusselLaboratory of Translational Genetics, VIB-KU Leuven, Leuven, Belgium.
Bram BoeckxLaboratory of Translational Genetics, VIB-KU Leuven, Leuven, Belgium.
Rogier SchepersLaboratory of Translational Genetics, VIB-KU Leuven, Leuven, Belgium.
Diether LambrechtsLaboratory of Translational Genetics, VIB-KU Leuven, Leuven, Belgium.
Luc DirixTranslational Cancer Research Unit, GZA Hospitals Antwerp, Antwerp, Belgium.
Denis LarsimontDepartment of Anatomopathology, Institut Jules Bordet, Brussels, Belgium.
Sophie VankerckhoveDepartment of Surgical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Valerio LucidiDepartment of Abdominal Surgery, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Baki TopalDepartment of Visceral Surgery, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Imane BachirDepartment of Anesthesiology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Vincent DonckierDepartment of Surgical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Giuseppe FlorisDepartment of Pathology, University Hospitals Leuven, Leuven, Belgium.
Peter VermeulenLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Herestraat 49, box 810, Leuven, 3000, Belgium.
Christine DesmedtLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Herestraat 49, box 810, Leuven, 3000, Belgium. Christine.desmedt@kuleuven.be.
KU Leuven · BEVIB-KU Leuven Center for Cancer Biology · BEInstitut Jules Bordet · BEGZA Ziekenhuizen Campus Sint-Augustinus · BEUniversité Libre de Bruxelles · BE

Funding

Fondation contre le Cancer C/2020/1441
6 · The paper itself

Abstract

Metastatic breast cancer (mBC) remains incurable and liver metastases (LM) are observed in approximately 50% of all patients with mBC. In some cases, surgical resection of breast cancer liver metastases (BCLM) is associated with prolonged survival. However, there are currently no validated marker to identify these patients. The interactions between the metastatic cancer cells and the liver microenvironment result in two main histopathological growth patterns (HGP): replacement (r-HGP), characterized by a direct contact between the cancer cells and the hepatocytes, and desmoplastic (d-HGP), in which a fibrous rim surrounds the tumor cells. In patients who underwent resection of BCLM, the r-HGP is associated with a worse postoperative prognosis than the d-HGP. Here, we aim at unraveling the biological differences between these HGP within ten patients presenting both HGP within the same metastasis. The transcriptomic analyses reveal overexpression of genes involved in cell cycle, DNA repair, vessel co-option and cell motility in r-HGP while angiogenesis, wound healing, and several immune processes were found overexpressed in d-HGP LM. Understanding the biology of the LM could open avenues to refine treatment of BC patients with LM.

Indexed as

Breast NeoplasmsLiver NeoplasmsTranscriptomeAgedBiomarkers, TumorFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMiddle AgedPrognosisTumor MicroenvironmentBiomarkers, TumorHistopathological growth patternLiver metastasisMetastatic breast cancerTranscriptomics

Identifiers

PMID38548918
PMCPMC11499425
OpenAlexW4393315590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.